Article
G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine - 1 May 2016
Fiala Ondrej, Buchler Tomas, Mohelnikova-Duchonova Beatrice, Melichar Bohuslav, Matejka Vit Martin, Holubec Lubos, Kulhankova Jana, Bortlicek Zbynek, Bartouskova Marie, Liska Vaclav, Topolcan Ondrej, Sedivcova Monika, Finek Jindrich
Abstract excerpt
The v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are found in 35-45 % of colorectal cancer (CRC) cases. Although the association between the RAS signaling and angiogenesis is well known, the negative predictive value of KRAS mutation has not been established in patients treated with bevacizumab. The aim of this study was to evaluate the association between specific KRAS mutation types and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.